Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Meribank Biotech Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:4724'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -138.1 Med: -0.71 Max: 24.6
Current: 24.6
During the past 8 years, the highest Debt-to-EBITDA Ratio of Meribank Biotech Co was 24.60. The lowest was -138.10. And the median was -0.71.
ROCO:4724's Debt-to-EBITDA is ranked worse than 95.08% of 305
companies
in the Biotechnology industry
Industry Median: 1.24
vs ROCO:4724: 24.60
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Meribank Biotech Co Debt-to-EBITDA Related Terms
Meribank Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Meribank Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Meribank Biotech Co (ROCO:4724) has a Debt-to-EBITDA of 32.23 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Meribank Biotech Co. According to the industry distribution chart, Meribank Biotech Co ranks #290 out of 305 companies in the Biotechnology industry, placing it in the top 95.1%.
Is Meribank Biotech Co's Debt-to-EBITDA too high?
Meribank Biotech Co's current Debt-to-EBITDA is 32.23. The Biotechnology industry median Debt-to-EBITDA is 1.24. Meribank Biotech Co's value of 32.23 is 2499.2% above this industry median. Based on the distribution chart, Meribank Biotech Co ranks #290 out of 305 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Meribank Biotech Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #290 out of 305 companies for Debt-to-EBITDA. This places Meribank Biotech Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.24. Meribank Biotech Co's value of 32.23 is 2499.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.24, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meribank Biotech Co's current Debt-to-EBITDA of 32.23 is 2499.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Meribank Biotech Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meribank Biotech Co's current Debt-to-EBITDA is 32.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$21.93, compared to a current price of NT$8.77 — trading 60% below its estimated fair value. The current Debt-to-EBITDA is 32.23 and 2499.2% above the Biotechnology industry median of 1.24. Meribank Biotech Co's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Debt-to-EBITDA is 32.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$8.77 is trading 60% below its estimated GF Value™ of NT$21.93.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
Debt-to-EBITDA: 32.23
GF Value™: NT$21.93 vs. price of NT$8.77 (60% below fair value)
Industry Position: 2499.2% above the Biotechnology median (#290 of 305)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
48GF Score
Get the complete analysis for ROCO:4724
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
